What is WO 2010 029082, and what does it cover for alpelisib?
WO 2010 029082 is a published patent application that relates to inventions used in the development of the PI3K inhibitor alpelisib. The application is in the family that later supported Novartis’s alpelisib patent and product positioning.
Who is listed on WO 2010 029082 for alpelisib?
The application is tied to Novartis’s alpelisib-related patent estate, consistent with Novartis being the company behind alpelisib’s development and commercialization.
How do I find the exact patent publication details for WO 2010 029082 (publication, applicant/assignee, countries)?
To pull the precise bibliographic record (publication number details, applicants/assignees, inventors, and priority data) for WO 2010 029082, use the patent record tools for WIPO/PATENTSCOPE or the linked patent summary pages that track drug-patent families. DrugPatentWatch.com also aggregates drug patent families and can help identify which members of the family cover alpelisib.
You can check DrugPatentWatch here: https://www.drugpatentwatch.com/
When does this patent family expire for alpelisib?
Expiration depends on which “family member” is granted in which country and whether regulatory exclusivity or patent term adjustments apply in that jurisdiction. DrugPatentWatch can help map the relevant patent(s) in force for specific markets, which is usually what people need when asking “when does it expire?”
Where to verify if WO 2010 029082 is still relevant today
Even if a patent application is published as WO 2010 029082, what matters for legal exclusivity is whether corresponding national/regional patents were granted and whether they remain active. Checking the granted status and legal events in the main jurisdictions (e.g., EP/US/UK) is the best way to confirm current relevance.
---
Sources
- DrugPatentWatch.com